Geem Duke, Hercules David, Pelia Ranjit S, Venkateswaran Suresh, Griffiths Anne, Noe Joshua D, Dotson Jennifer L, Snapper Scott, Rabizadeh Shervin, Rosh Joel R, Baldassano Robert N, Markowitz James F, Walters Thomas D, Ananthakrishnan Ashwin, Sharma Garima, Denson Lee A, Hyams Jeffrey S, Kugathasan Subra
Division of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Healthcare of Atlanta, Atlanta, Georgia.
Division of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia.
Clin Gastroenterol Hepatol. 2024 Feb;22(2):368-376.e4. doi: 10.1016/j.cgh.2023.08.042. Epub 2023 Oct 5.
BACKGROUND & AIMS: The evolution of complicated pediatric Crohn's disease (CD) in the era of anti-tumor necrosis factor (aTNF) therapy continues to be described. Because CD progresses from inflammatory to stricturing (B2) and penetrating (B3) disease behaviors in a subset of patients, we aimed to understand the risk of developing complicated disease behavior or undergoing surgery in relation to aTNF timing and body mass index z-score (BMIz) normalization.
Multicenter, 5-year longitudinal data from 1075 newly diagnosed CD patients were analyzed. Descriptive statistics, univariate and stepwise multivariate Cox proportional hazard regression (CPHR), and log-rank analyses were performed for risk of surgery and complicated disease behaviors. Differential gene expression from ileal bulk RNA sequencing was correlated with outcomes.
Stricturing complications had the largest increase: from 2.98% to 10.60% over 5 years. Multivariate CPHR showed aTNF exposure within 3 months from diagnosis (hazard ratio [HR], 0.33; 95% CI, 0.15-0.71) and baseline L2 disease (HR, 0.29; 95% CI, 0.09-0.92) to be associated with reduced B1 to B2 progression. For children with a low BMIz at diagnosis (n = 294), multivariate CPHR showed BMIz normalization within 6 months of diagnosis (HR, 0.47; 95% CI, 0.26-0.85) and 5-aminosalicyclic acid exposure (HR, 0.32; 95% CI, 0.13-0.81) were associated with a decreased risk for surgery while B2 (HR, 4.20; 95% CI, 1.66-10.65) and B2+B3 (HR, 8.24; 95% CI, 1.08-62.83) at diagnosis increased surgery risk. Patients without BMIz normalization were enriched for genes in cytokine production and inflammation.
aTNF exposure up to 3 months from diagnosis may reduce B2 progression. In addition, lack of BMIz normalization within 6 months of diagnosis is associated with increased surgery risk and a proinflammatory transcriptomic profile.
在抗肿瘤坏死因子(aTNF)治疗时代,儿童复杂性克罗恩病(CD)的演变仍在持续研究中。由于部分患者的CD会从炎症性病变发展为狭窄性(B2)和穿透性(B3)病变行为,我们旨在了解与aTNF治疗时机和体重指数z评分(BMIz)正常化相关的发生复杂性疾病行为或接受手术的风险。
分析了来自1075例新诊断CD患者的多中心5年纵向数据。对手术风险和复杂性疾病行为进行描述性统计、单因素和逐步多因素Cox比例风险回归(CPHR)以及对数秩分析。回肠大量RNA测序的差异基因表达与预后相关。
狭窄并发症的增加最为显著:5年内从2.98%增至10.60%。多因素CPHR显示,诊断后3个月内接受aTNF治疗(风险比[HR],0.33;95%置信区间[CI],0.15 - 0.71)以及基线L2疾病(HR,0.29;95% CI,0.09 - 0.92)与B1向B2进展的减少相关。对于诊断时BMIz较低的儿童(n = 294),多因素CPHR显示诊断后6个月内BMIz正常化(HR,0.47;95% CI,0.26 - 0.85)和使用5 - 氨基水杨酸(HR,0.32;95% CI,0.13 - 0.81)与手术风险降低相关,而诊断时为B2(HR,4.20;95% CI,1.66 - 10.65)和B2 + B3(HR,8.24;95% CI,1.08 - 62.83)则增加手术风险。BMIz未正常化的患者在细胞因子产生和炎症相关基因方面富集。
诊断后3个月内接受aTNF治疗可能会减少B2进展。此外,诊断后6个月内BMIz未正常化与手术风险增加及促炎转录组特征相关。